Dr. Blackman co-founded Day One Biopharmaceuticals in 2018 with a vision to identify, acquire, and develop promising new treatments to address childhood cancers. Under Dr. Blackman’s leadership, Day ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback